Pregled bibliografske jedinice broj: 1012254
MPIVAS
mPIVAS // The 24th European Congress of Psychiatry (EPA 2016)
Madrid, Španjolska, 2016. str. - (predavanje, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 1012254 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
MPIVAS
Autori
Rojnic Kuzman, Martina ; Andlauer, Olivier ; Burnmaister, Kai ; Dvoracek, Boris ; Lencer6, Katja Koelkebeck, Rebekka ; Maric Bojovic, Nadja ; Nawka, Alexander ; Pantovic, Maja ; Riese, Florian ; Aukst Margetić, Branka ; Bošnjak, Dina ; Ćelić Ružić, Mirela ; Ćurković, Marko ; Grubišin, Jasmina ; Madžarac, Zoran ; Makarić, Porin ; Petrić, Daniela ; Radić, Krešimir ; Savić, Aleksndar
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
The 24th European Congress of Psychiatry (EPA 2016)
/ - , 2016
Skup
The 24th European Congress of Psychiatry (EPA 2016)
Mjesto i datum
Madrid, Španjolska, 12.03.2016. - 15.03.2016
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
mPIVAS
Sažetak
As a part of the mHealth Psycho educational Intervention Versus Antipsychotic-Induced Side Effects (mPIVAS) project (www.psylog.eu), we developed the mobile application (PsyLOG) based on a mobile “Smartphone” technology to monitor antipsychotic-induced adverse effects, available in six languages. To test the applicability of the PsyLOG app in our clinical practice, we performed a clinical trial among up to 80 early psychosis patients in Croatia, Germany and Serbia. Patients were grouped according to methods of treatment (PsyLOG app vs. treatment as usual (TAU)) and followed-up over six months in four points regarding psychopathology, side effects and the adherence to treatment using standardized psychiatric scales. Our results showed that the PsyLOG group detected significantly more side effects compared to the TAU group during follow up, while no differences in psychopathology and adherence between the groups were observed. Furthermore, the PsyLOG group detected more side effects using the PsyLOG than it was observed using the standardized psychiatric scales. Considering its efficacy and shorter detection period in assessing side effects compared to standardized psychiatric scales, the PsyLOG can be a useful tool for clinical practice, especially when patients are treated with combined therapy (and thus having more diverse side effects), and for clinical research. We will also show our preliminary results from a new cross sectional trial among patients treated with combinations of antipsychotics and other drugs in a naturalistic setting followed up to one month with PsyLOG.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Klinika za psihijatriju Vrapče,
Klinički bolnički centar Zagreb,
Klinički bolnički centar Rijeka
Profili:
Branka Aukst Margetić
(autor)
Martina Rojnić Kuzman
(autor)
Daniela Petrić
(autor)
Zoran Madžarac
(autor)
Marko Ćurković
(autor)
Jasmina Grubišin
(autor)